Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety of Acidform Lubricant in HIV-Uninfected Women

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00850837
First received: February 24, 2009
Last updated: December 2, 2013
Last verified: December 2013

February 24, 2009
December 2, 2013
February 2009
Not Provided
  • Measured endogenous antimicrobial activity [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Measured levels of mediators of host defense, including defensins, cytokines, and chemokines in CVL [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00850837 on ClinicalTrials.gov Archive Site
  • Extent and duration of buffering measured by vaginal pH [ Time Frame: Prior to and 2 hours after first application ] [ Designated as safety issue: No ]
  • Changes in epithelial integrity after Acidform and HEC application [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Changes in vaginal flora following Acidform and HEC application [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Antiviral activity in CVL following Acidform and HEC application [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Safety of Acidform Lubricant in HIV-Uninfected Women
Safety of Acidform Lubricant (Amphora) in Women at Low Risk for HIV-1 Infection

Topical microbicides, substances that kill microbes, are being studied to prevent sexual transmission of HIV and other disease pathogens. In the future, topical microbicides may be applied vaginally to prevent both acquisition and transmission of HIV and other sexually transmitted infections (STIs). The purpose of this study is to compare the safety of daily applications of Acidform lubricant and HEC gel in healthy women at low risk for HIV infection and assess the effect of a microbicide candidate on the natural immunity women have to STI pathogens.

A new approach to HIV prevention currently being studied is the use of topical microbicides. This study will measure the mucosal response to daily intravaginal applications of Acidform lubricant and HEC gel in two groups of healthy women at low risk for HIV infection.

The duration of this study for each participant is 3 weeks. Study participants will be randomly assigned to one of two study groups. Group 1 participants will apply Acidform lubricant twice daily for 14 consecutive days between menses. Group 2 participants will apply HEC gel for 14 consecutive days between menses.

After screening and study entry, study visits will occur on Days 7, 14, and 21. Study entry will occur 2 to 6 days following the menses and within 45 days of screening. Medical and sexual history, a pelvic exam, cervicovaginal lavage sample collection, blood collection, vaginal pH testing, STI testing, and adverse effect reporting will occur at all visits. Cytobrush collection, vaginal swab, and cervical biopsy will occur at selected visits. All participants will be asked to complete a diary throughout the study; this diary will be reviewed at all study visits. A Pap smear will be obtained at screening if documentation of a negative Pap smear result within the last year is not available.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
  • Drug: Acidform Lubricant
    5 g application of acid buffered gel (pH = 3.5)
    Other Name: Amphora
  • Drug: HEC gel
    5 g application of hydroxyethylcellulose gel
  • Experimental: 1
    Participants will apply Acidform lubricant twice daily for 14 consecutive days between menses
    Intervention: Drug: Acidform Lubricant
  • Placebo Comparator: 2
    Participants will apply HEC gel twice daily for 14 consecutive days between menses
    Intervention: Drug: HEC gel

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
35
Not Provided
Not Provided

Inclusion Criteria:

  • Normal menstrual history with regular cycles and with a minimum of 21 days between menses
  • Low risk for HIV/STI infection. More information on this criterion can be found in the protocol.
  • Agree to abstain from vaginal and anal intercourse and to not use vaginal products within 48 hours prior to study entry and for the duration of the study

Exclusion Criteria:

  • HIV-infected
  • Menopausal
  • Currently using hormonal contraception or have used hormonal contraception within 2 months of study entry
  • Menstruating at screening or enrollment visits
  • Urinary tract infection at screening
  • Positive chlamydia, gonorrhea, or trichomonas result at screening
  • Abnormal Pap smear
  • Clinically detectable genital abnormality. More information on this criterion can be found in the protocol.
  • Currently participating in a research study of other vaginal products
  • History of intermenstrual bleeding within 3 months prior to study entry
  • Previous gynecologic surgery or have received treatment for syphilis, genital herpes, chlamydia, gonorrhea, trichomonas, or genital warts within 6 months prior to study entry
  • Received treatment for Candida, bacterial vaginosis, or urinary tract infection within 1 month prior to study entry
  • Have douched or used vaginal products, including lubricants, feminine hygiene products, vaginal drying agents, and sex toys within 48 hours prior to study entry
  • Vaginal or anal intercourse during the 48 hours prior to study entry
  • Oral antibiotics within 7 days of study entry
  • Pregnant, less than 6 months postpartum, or breastfeeding
Female
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00850837
Keller 069551 AF020, U01 AI069551, 10740, AF 020
Yes
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Principal Investigator: Marla Keller, MD Albert Einstein College of Medicine of Yeshiva University
National Institute of Allergy and Infectious Diseases (NIAID)
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP